stockrow
Friday 6 November 2026
Export SBFM’s income statement to Excel — free account
Sunshine Biopharma, Inc.
SBFM Healthcare Drug Manufacturers Specialty & Generic
Sunshine Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.3 million, up 4.11% from fiscal 2024.
- Revenue
- −1.56%
- EPS
- +70.9%
- Free cash flow
- +49.4%
Quarter to June 2026, against a year earlier
2.71
0.08
−2.87%
Follow SBFM
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.33 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.18 | 0.14 | 0.14 | 0.08 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(9.10) | (3.17) | (2.46) | (3.12) | |
P/B ratio |
0.28 | 0.22 | 0.24 | 0.10 | |
Price to Tangible BV |
0.31 | 0.24 | 0.26 | 0.11 | |
EV/Sales |
(0.02) | (0.06) | 0.00 | (0.25) | |
EV/EBITDA |
0.13 | 0.51 | 0.00 | 1.85 | |
EV/Operating CF |
0.09 | 0.40 | (0.01) | 1.68 | |
EV/FCF |
0.08 | 0.34 | (0.01) | 1.62 | |
Quick Ratio |
2.02 | 1.95 | 1.86 | 3.16 | |
Current Ratio |
4.20 | 4.17 | 4.22 | 5.46 | |
Net Debt/EBITDA |
21.36 | 5.85 | 5.24 | 8.96 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.21 | 1.20 | 1.24 | 1.08 | |
Operating CF/Net income |
0.84 | 0.75 | 1.67 | 0.59 | |
Capex/Depreciation |
(0.04) | (0.22) | (1.36) | (0.07) | |
Research and Development Expense of Revenue |
1.27% | 0.86% | 0.39% | 0.14% | |
Selling, General and Administrative Expense of Revenue |
36.00% | 73.02% | 42.87% | 42.62% | |
Intangible Assets out of Total Assets |
0.06 | 0.06 | 0.07 | 0.05 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 1.05% | |
Graham Net Nets |
3.04 | 3.87 | 3.60 | 8.57 | |
Graham Number |
4,658.69 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
305.14% | (116.86%) | (120.63%) | (464.39%) | |
Free Cash Flow Yield |
(117.81%) | (120.53%) | (126.31%) | (193.00%) | |
Revenue per Share |
413.04 | 412.36 | 330.16 | 135.63 | |
Operating CF per Share |
(32.75) | (77.69) | (84.58) | (13.44) | |
Capex per Share |
(1.05) | (2.41) | (4.27) | (0.07) | |
Free Cash Flow per Share |
(33.80) | (80.11) | (88.84) | (13.52) | |
Cash per Share |
408.18 | 438.62 | 282.16 | 201.29 | |
Shareholders Equity per Share |
1,061.38 | 1,107.62 | 878.23 | 403.19 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1,061.38 | 1,107.62 | 878.23 | 403.19 | |
Free Cash Flow |
(0.77) | (1.67) | (2.18) | (0.92) | |
Working Capital |
21.32 | 20.41 | 18.91 | 25.05 | |
Capital Expenditures |
(0.02) | (0.05) | (0.10) | (0.01) | |
Net Current Asset Value |
20.68 | 19.81 | 18.37 | 24.57 | |
EV/EBIT |
0.09 | 0.34 | 0.00 | 1.53 | |
Capex to Sales |
0.00 | 0.01 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
3.69 | 3.66 | 3.73 | 3.81 | |
Average Payables |
5.15 | 5.60 | 5.06 | 4.83 | |
Average Inventory |
11.94 | 12.38 | 12.51 | 12.57 | |
Average Assets |
30.77 | 30.32 | 28.56 | 32.80 | |
Average Common Equity |
24.61 | 23.26 | 22.10 | 26.60 |
Columns are period end dates · fundamentals updated 2 Nov 2026